BGIM
TTNP

Brandywine Global Investment Management’s Titan Pharmaceuticals TTNP Stock Holding History

Brandywine Global Investment Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3
Closed -$39K – 970
2016
Q4 		$39K Buy
+3
New +$50.5K ﹤0.01% 827

Other funds holding TTNP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brandywine Global Investment Management's TTNP Position: Q1 2017 in Review

Brandywine Global Investment Management sold out of Titan Pharmaceuticals (TTNP) in Q1 2017, closing a stake of 3 shares — an estimated $39K sold.

Brandywine Global Investment Management first reported a position in TTNP in Q4 2016 and held it in 1 quarter. The position peaked at $39K in Q4 2016. 40 funds tracked by Wall St. Rank hold TTNP as of Q1 2017.

  • Brandywine Global Investment Management reported no remaining Titan Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Brandywine Global Investment Management sold 3 Titan Pharmaceuticals shares in Q1 2017, an estimated $39K.
  • Brandywine Global Investment Management first reported a position in Titan Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Brandywine Global Investment Management's Titan Pharmaceuticals position peaked at $39K in Q4 2016.
  • 40 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2017.

Based on Brandywine Global Investment Management's 13F filing for Q1 2017, filed 15 May 2017.